BioCentury
ARTICLE | Company News

Galapagos regains GLPG1205 rights from J&J

December 17, 2014 2:16 AM UTC

Galapagos N.V. (Euronext:GLPG; Pink:GLPYY) said Johnson & Johnson (NYSE:JNJ) returned all rights to compounds targeting G protein-coupled receptor 84 ( GPR84) covered under the companies' partnership, including GLPG1205, a selective inhibitor of GPR84.

J&J spokesperson Brian Kenney said the decision was mutual between the companies and a "strategic portfolio prioritization decision" for J&J. ...